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placebo on acylation stimulating protein receptor
gene expression in type 2 diabetics
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Mohammad Reza Eshraghian4, Mohammad Hassan Javanbakht1,2, Maryam Chamari1,2 and Abolghassem Djazayery1,3Abstract
Background: This randomized controlled trial investigated the role of omega-3 supplementation on C5L2 gene
expression in type 2 diabetics.
Methods: Subjects in the omega-3 group received 4 g omega-3 per day and subjects in the placebo group took
four capsules of placebo per day for 10 weeks. Gene expression was measured by RT- PCR at the beginning and
end of the study.
Results: The results of this study show depletion in the omega-3 group, but the mean difference between two
groups was not significant.
Conclusions: Understanding the effect of the omega-3 pathway could contribute to targeting treatment of diabetes
and its comorbidities.
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Diabetes is a metabolic disorder that influences white
adipose tissue (WAT) secretory adipokines such as lep-
tin, adiponectin and acylation stimulating protein (ASP)
[1]. ASP is an adipokine produced by adipose tissue that
affects glucose metabolism and fat storage. ASP gener-
ally increases with obesity, type 2 diabetes, and cardio-
vascular disease [2]. In recent years, adipose tissue has
been considered an endocrine organ responsible for the
development of chronic diseases such as diabetes. In the
two decades after the discovery of adipokines, the rela-
tionship between pancreatic cells and adipose tissue has
been found to be a two-way pathway [3].
C5L2 is a protein with high chemical absorption that
connects via separate sites to receptors such as C3a, C5a,
C5a des-Arg, and C3a des-Arg (ASP). Triglyceride synthe-
sis, however, occurs only when it connects to ASP [4].* Correspondence: mjalali87@yahoo.com
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distribution, and reproduction in any mediumC5L2 is an orphan G protein-coupled receptor (GPCR)
family and has a high affinity to bind with ASP. It is a
functional receptor for ASP and, if a signaling pathway ex-
ists via receptors, external agonists and antagonists can be
clearly identified [5]. C5L2 knock-out mice show in-
creased food intake, increased WAT, altered glucose/insu-
lin metabolism, and change in adiponectin and insulin
gene expression, which could lead to the development of
insulin resistance. Disruption of C5L2 gene-induced
macrophage presence in WAT contributes to obesity-
associated disorders [6].
Factors that alter insulin resistance can induce changes
in C5L2 gene expression [7]. Thiazolidinediones are
anti-diabetic drugs with PPARγ agonistic characteristics
[8]. Previous studies examined how thiazolidinediones
such as rosiglitazone increase C5L2 mRNA and cell sur-
face proteins [9]. Omega-3 fatty acids decrease blood tri-
glyceride levels [10,11]. Regular intake of omega-3 may
reduce the complications of diabetes [12,13]. The effect
of pharmacological doses, such as anti-inflammatory ef-
fects, however, are not been clearly understood at the
molecular level [11]. Recent studies show that PPARγ ised Central Ltd. This is an open access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
Table 1 Primers sequencing and information
Gene name Sequence Length TM CG%
C5L2 forward GCTGCAGTGTGTGGTGGACTAC 22 56.7 59.1%
C5L2 reverse AAGAAACCGGATGGCAGTCA 20 56.6 50.0%
Gap DH forward AAGGTGAAGGTCGGAGTCAAC 21 54.3 52.4%
Gap DH reverse GGGGTCATTGATGGCAACAATA 22 58.0 45.5%
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creases with n-3 fatty acids treatment [11,14].
It seems that omega-3 and thiazolidinediones use the
same mechanism for PPARγ activation and the molecu-
lar effects of this agent have not been clearly explained.
The present study examines the effect of omega-3 sup-
plementation on C5L2 gene expression in type 2 diabetic
patients.Methods
Patients and supplementation
Forty-five type 2 diabetic mellitus (T2DM) patients (17
males, 28 females, 40–65 years of age; mean age: 53.77 yr)
enrolled in this survey. One patient subsequently with-
drew. Patients were informed of the goal and possible
risks of the study and that they were free to withdraw at
any time. This study was approved by the Tehran Univer-
sity of Medical Sciences (TUMS) ethical committee (ID:
15176). Informed consent forms were obtained from all
participants after the purpose of the study was explained
to them. This study registered on www.clinicaltrial.org as
NCT01478776.
All patients were diagnosed by an endocrinologist based
on fasting blood sugar. The exclusion criterion was having
consumed omega-3 supplements within three months of
the beginning of the study. No patient had complications
of diabetes, thyroid disorder, nor did they use anti-obesity
drugs. None were pregnant or breastfeeding. None was re-
ceiving thiazolidinediones or insulin therapy. All patients
were requested to maintain their usual exercise and diet-
ary habits. All participants were treated with metformin
and glibenclamide.Table 2 Anthropometric data of patients and controls
Omega-3 group
Before
Age (years) 54.23 ± 1.64
Weight (Kg) 69.21 ± 2.84 68
Height (cm) 162 ± 2.11
Waist circumflex (cm) 86.41 ± 2.33 86
Hip circumflex (cm) 102.54 ± 1.62 101
BMI (kg/m2) 26.19 ± 0.78 26
All values are expressed as means ± SEM.All participants were divided into two randomly allo-
cated groups (omega-3 or placebo) by random permuted
blocks within the strata (BMI) method. The omega-3
group received 4 capsules of omega-3 (640 mg EPA,
DHA, ALA, vitamin E) daily, and the placebo group took
4 placebo capsules per day for 10 wk. PBMC isolation,
RNA extraction, cDNA synthesis, and real-time PCR for
gene expression were done as described in previous stud-
ies [15,16]. Sequencing and information about primers are
shown in Table 1.
Statistical analysis
Statistical analysis was done using SPSS 18.0 for win-
dows. Data was expressed as mean ± SD. The Kolmogorov–
Smirnov distribution test was used for departure from
normality and nonparametric tests were used for data ana-
lyses that did not show normal distribution. Variables
within and between groups were analyzed using the two-
related sample test (Wilcoxon) and the two-independent
sample test (Mann-Whitney U). If data had a normal distri-
bution, the independent sample test and paired t-test were
used for comparisons between groups, before and after
treatment, and within groups, respectively. P-value < 0.05
was considered statistically significant.
Results and discussion
General information
A total of 44 patient volunteers (61.3% female, 38.6%
male) were enrolled in this study. Anthropometrics of the
treatment and placebo groups are shown in Table 2. There
were no statistically significant differences in age, weight,
height, BMI, waist and hip circumferences between the
omega-3 and placebo groups (P = NS).Placebo group
After Before After
- 53.32 ± 1.45 -
.96 ± 2.91 63.57 ± 2.65 63.60 ± 2.78
- 156 ± 1.37 -
.15 ± 2.44 83.66 ± 2.10 83.16 ± 2.24
.83 ± 1.66 97.25 ± 1.74 97.22 ± 1.81
.11 ± 0.84 25.93 ± 0.92 25.95 ± 0.98
Table 3 Δ_CT and mean of C5L2 gene expression in PBMC
Omega-3 (n=22) Placebo (n=22) p valuea‡
C5L2 gene expression
in PBMC
Before 10.19 ± 2.87 10.90 ± 2.87 0.26
After 9.16 ± 1.20 9.34 ± 1.07 0.77
Difference −1.03 ± 3.65 −1.55 ± 2.99 0.61
p valueb* 0.01 0.001
Mean of C5L2 gene
expression in PBMC
0.48 ± 0.49 0.44 ± 0.53 0.66
Data are reported as means ±SD. Δ_CT = CT of target gene – CT of _GAP DH.
*two related sample tests (Wilcoxon) ‡ two independent sample tests (Mann Whitney U).
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The results showed that, by the end of the study, C5L2 gene
expression as shown with cycle threshold modification
between C5L2 and GAP DH, had decreased significantly
in both the omega-3 and placebo supplemented groups
(P = 0.01 and P = 0.001, respectively). Gene expression
in the two groups were calculated with 2-ΔΔct, before and
after treatment showed no significant difference (P = 0.66)
(Table 3, Figure 1). The Prism software was used for ex-
plain fold changes modifications.
In this study, 44 diabetic patients enrolled in a 10 wk
omega-3 and placebo supplementation study to deter-
mine the effect of omega-3 supplementation on C5L2.
Fisette et al. have demonstrated that changes in ASP can
influence diet-induced insulin resistance. Changes in the
ASP-C5L2 pathway in obesity could accelerate obesity
and co-morbidities such as T2DM and atherosclerosis
[17]. Augmentation in ASP and TG in morbidly obese
patients can alter the profile of the C5L2 receptor, ASP
gene expression, and metabolic factors that show a com-
pensatory response in patients [18]. Studies on knock-
out mice show that C5L2 changes insulin expression
and glucose metabolism and contributes to changes in
insulin and adiponectin gene expression, and insulin re-
sistance [6].
Insulin resistance and exercise change muscle function
in obese diabetic men, contributing to changes C5L2
gene expression. These results indicate that insulin sen-
sitivity may allow coupling of C5L2 levels to fat storage
and utilization [7]. Acylation-stimulating protein and its
















Figure 1 Gene expression of C5L2 in omega-3 and
placebo groups.adiposities, sexual hormones such as progesterone and
testosterone down-regulate C5L2. This is in contrast to
thiazolidinediones such as rosiglitazone that up-regulate
both C5L2 mRNA and C5L2 cell-surface protein [9]. ASP
resistance is a product of sex-steroid hormones via C5L2
and may contribute to changes in the function of adipose
tissue and insulin resistance in humans [19]. Tom et al.
examined the effects of ASP on adipocytes and macro-
phages. Treatment with ASP on adipocytes had no effect
on ligand binding of C5L2. Their results demonstrate
ASP-induced inflammatory cytokines in adipocytes via
PI3 kinase- and NFκB-dependent pathways, particularly at
high physiologic doses [20].
In mature adipocytes treated with multiple doses of
oleate or palmitate for 18 h, the C5L2 mRNA expression
levels did not significantly decrease. These results sug-
gest that down-regulation of C5L2 mRNA and protein
may relate to impaired insulin [21]. Fusakio et al. [22]
demonstrated that naive natural killer cells express C5aR
and C5L2 mRNA, but did not express protein. Induced
sepsis with Escherichia coli did not change C5L2 expres-
sion, but had a significant effect on IFN-γ and TNF-α
serum levels. Zheng et al. [23] investigated C5L2 poly-
morphism in Chinese subjects and demonstrated that
the 698CT genotype of C5L2 may be related to T2DM.
The heterozygous expression of this gene may relate to
metabolic abnormalities.
The demonstration of a functional ASP receptor using
gain- and loss-of-function examinations is an important
step in understanding the mechanisms of ASP function.
Future studies of C5L2 activation and signaling, especially
ligand binding, may help find C5L2 agonists-antagonists
that might be modulators of the ASP pathway [5]. Al-
though there is much left to learn about the role of C5L2
in humans, this investigation suggests that C5L2 may play
a role in metabolic syndrome and diabetes.Conclusions
This study was a clinical trial of the effects of omega-3
supplementation on C5L2 gene expression in diabetic
patients. It is postulated that omega-3 induced down-
regulation of C5L2 gene expression in the omega-3 group.
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